This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nakata, B. Articles by Hirakawa, K. Search for Related Content PubMed PubMed Citation Articles by Nakata, B. Articles by Hirakawa, K.

Clinical Significance of Serum Soluble Intercellular Adhesion Molecule 1 in Gastric Cancer

First Department of Surgery [B. N., T. H., T. Su., Y. O., M. Y., K. M., T. Sa., T. I., K. H.] and Department of Oncology, Institute of Geriatrics and Medical Science [Y. K.], Osaka City University Medical School, Osaka 545-8585, Japan

We studied the correlation between serum soluble intercellular molecule 1 (sICAM-1) and clinicopathological features in patients with gastric cancer. The impact of sICAM-1 on prognosis was also evaluated. The sera from 224 patients with gastric cancer, 44 healthy individuals, and 35 patients with benign gastrointestinal diseases (4 patients with submucosal stomach tumors, 6 patients with gastric ulcers, 1 patient with Crohn disease, 2 patients with ulcerative colitis, 7 patients with gall stones, 5 patients with chronic pancreatitis, and 10 patients with liver cirrhosis) were measured for sICAM-1 titer using a sandwich enzyme immunoassay method. There was no correlation between the serum titer of sICAM-1 and the age or gender of healthy controls. Among patients with benign gastrointestinal diseases, the patients with liver cirrhosis had a significantly higher mean serum sICAM-1 titer than that of healthy controls (P < 0.0001). The mean serum sICAM-1 titer of all patients with gastric cancer was not significantly different from that of healthy controls. However, among the patients with stage IV and recurrent disease, the serum sICAM-1 titer of those with hematogenous metastasis was significantly higher than that of patients without hematogenous metastasis (P = 0.001). The patients with a high serum sICAM-1 titer of more than 304 ng/ml (mean of healthy controls plus SD) showed a significantly worse prognosis than patients with a low serum sICAM-1 titer (P = 0.010). Nevertheless, serum sICAM-1 titer was not an independent predictor of prognosis by multivariate analysis. In conclusion, serum sICAM-1 cannot be used as a tumor marker for early diagnosis. However, sICAM-1 in sera may still be worthwhile to measure for monitoring hematogenous metastasis.

This article has been cited by other articles:

				Y. Toiyama, C. Miki, Y. Inoue, Y. Okugawa, Y. Koike, T. Yokoe, K. Tanaka, and M. Kusunoki Soluble Intercellular Adhesion Molecule-1 as a Prognostic Marker for Stage II Colorectal Cancer Patients Ann. Surg. Oncol., June 1, 2008; 15(6): 1617 - 1624. [Abstract] [Full Text] [PDF]

				F. Akcay, S. Taysi, C. Uslu, Y. Dogru, and K. Gumustekin Levels of Soluble Intercellular Adhesion Molecule-1 and Total Sialic Acid in Serum of Patients with Laryngeal Cancer Jpn. J. Clin. Oncol., December 1, 2001; 31(12): 584 - 588. [Abstract] [Full Text] [PDF]